In COVID-19-induced
acute respiratory distress syndrome, the lungs are incapable of filling with sufficient air, leading to
hypoxemia that results in high mortality among hospitalized patients. In clinical trials,
low-molecular-weight heparin was administered via a specially designed soft-mist
inhaler device in an investigator initiated, single-center, open-label, phase-IIb clinical trial. Patients with evidently worse clinical presentations were classed as the "Device Group"; 40 patients were given
low-molecular-weight heparin via a soft mist
inhaler at a dose of 4000 IU per administration, twice a day. The Control Group, also made up of 40 patients, received the standard
therapy. The predetermined severity of
hypoxemia and the peripheral oxygen saturation of patients were measured on the 1st and 10th days of treatment. The improvement was particularly striking in cases of severe
hypoxemia. In the 10-day treatment,
low-molecular-weight heparin was shown to significantly improve breathing capability when delivered via a soft-mist
inhaler.